References
- Leibbrandt A, Penninger JM. RANK/RANKL: regulators of immune responses and bone physiology. Ann NY Acad Sci 2008;1143:123–150
- Wright HL, McCarthy HS, Middleton J, et al. RANK, RANKL and osteoprotegerin in bone biology and disease. Curr Rev Musculoskelet Med 2009;2:56–64
- Khosla S, Westendorf JJ, Oursler MJ. Building bone to reverse osteoporosis and repair fractures. J Clin Invest 2008;118:421–428
- Seeman E, Delmas PD. Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250–2261
- Wada T, Nakashima T, Hiroshi N, et al. RANKL–RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006;12:17–25
- Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007;22:465–475
- McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165:1762–1768
- Anderson DM, Maraskovsky E, Billingsley WL, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997;390:175–179
- Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165–176
- Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597–3602
- Lomaga MA, Yeh WC, Sarosi I, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999;13:1015–1024
- Oyajobi BO, Anderson DM, Traianedes K, et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor κB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res 2001;61:2572–2578
- Kostenuik, PJ, Nguyen HQ, McCabe J, et al. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2009;24:182–195
- Lipton A, Steger GG, Figueroa J, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer related bone metastases. J Clin Oncol 2007;25:4431–4437
- Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299–1309
- Marathe A, Peterson MC, Mager DE. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther 2008;326:555–562
- Ta HM, Nguyen GTT, Jin HM, et al. Structure-based development of a receptor activator of nuclear factor-kB ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosis. Proc Natl Acad Sci USA 2010;107:20281–20286
- Liu C, Walter TS, Huang P, et al. Structural and functional insights of RANKL-RANK interaction and signaling. J Immunol 2001;184:6910–6919
- Chun T, Byun HJ, Chung HY, et al. The effect of soluble LAG-3 (CD223) treatment in fetal thymic organ culture. Biotechnol Lett 2004;26:1371–1377
- Ory DS, Neugeboren BA, Mulligan RC. A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. Proc Natl Acad Sci USA 1996;93:11400–11406
- Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab. Nat Rev Drug discov 2012;11:401–419
- Zhang S, Liu C, Huang P, et al. The affinity of human RANK binding to its ligand RANKL. Arch Biochem Biophys 2009;487:49–53